Promising New Therapies Offer Hope for Myelin Repair in Multiple Sclerosis and Beyond
For individuals living wiht Multiple Sclerosis (MS) and other neurological conditions,the prospect of repairing damaged nerve fibers - rather than simply slowing their decline – represents a paradigm shift in treatment. Researchers at the University of California, Riverside (UCR) and the University of Illinois at Urbana-Champaign (UIUC) are at the forefront of this exciting development, having identified two compounds, K102 and K110, with the potential to restore myelin – the protective sheath around nerve fibers crucial for efficient signal transmission. These discoveries, now being advanced by biotech firm Cadenza Bio, offer a beacon of hope for limiting long-term disability and improving the lives of millions.
The Challenge of Myelin Damage and the promise of Repair
MS is an autoimmune disease where the body’s immune system attacks myelin, disrupting communication between the brain and the rest of the body. This damage leads to a range of symptoms, including muscle weakness, fatigue, vision problems, and cognitive difficulties. Current MS treatments primarily focus on managing symptoms and slowing disease progression, frequently enough by suppressing the immune system.However, they rarely address the underlying issue of myelin damage and nerve fiber loss.
“The conventional approach has been about protecting neurons,” explains Dr. Pranav Tiwari-Woodruff,a professor at UCR and a lead researcher on the project. “But what if we could actually repair the damage? That’s the question that drove our research.”
K102, the more advanced of the two compounds, has demonstrated a remarkable ability to promote myelin restoration in preclinical studies. By facilitating the rebuilding of this crucial protective layer, K102 aims to improve nerve signal transmission and perhaps reverse some of the debilitating effects of MS.
“K102 is showing important promise in addressing the core pathology of MS,” adds Dr. John Katzenellenbogen, a professor at UIUC and Dr. Tiwari-Woodruff’s long-time collaborator. “Restoring myelin isn’t just about slowing down the disease; it’s about potentially regaining lost function.”
K110: Expanding the Therapeutic Horizon
While K102 is currently the lead candidate for MS treatment, K110 is also generating considerable excitement. Dr. Tiwari-Woodruff notes that K110 exhibits slightly different effects on the central nervous system, suggesting it may be especially well-suited for conditions like spinal cord injury and traumatic brain injury.
“K110’s unique profile opens up possibilities beyond MS,” she explains. “We’re actively exploring its potential to address a broader range of neurological disorders where nerve damage is a central feature.”
From Academic Finding to Biotech Innovation: A Collaborative Success Story
The journey from initial discovery to potential clinical application wouldn’t have been possible without a collaborative spirit and strategic funding.A pivotal moment came with a grant from the National MS Society‘s Fast Forward program, wich is specifically designed to accelerate the commercialization of promising MS therapies.
Fast Forward’s support enabled the researchers to generate the robust data necessary to secure licensing rights for K102 and K110 with Cadenza Bio, a biotechnology company dedicated to developing innovative neurological therapies. UCR and UIUC jointly hold the patents, with Cadenza Bio holding an exclusive, worldwide license to develop and commercialize the compounds.
Grace Yee, Assistant Director of Technology Commercialization at UCR, emphasizes the importance of the collaborative effort. “The combined expertise of UCR, UIUC, and the National MS Society, coupled with strategic guidance from our entrepreneurs-in-residence, was instrumental in attracting investor interest and ultimately securing the licensing agreement with Cadenza Bio.”
Cadenza Bio: Driving the Next Phase of Development
Cadenza Bio recognizes the transformative potential of these discoveries. “We where deeply impressed by the possibility of shifting from simply slowing axon damage to actively repairing it,” says Elaine Hamm, Chief Operating Officer at Cadenza Bio. “This is the future of neurological treatment,and it’s why we’re so committed to bringing K102 and K110 to patients in need.”
Currently, Cadenza Bio is focused on completing the necessary non-clinical studies required to support a first-in-human clinical trial for K102. The team is optimistic that clinical trials could begin in the near future.
A Decade of Dedication and a Vision for the Future
The collaboration between Dr. Tiwari-Woodruff and Dr. Katzenellenbogen spans more than 12 years, a testament to their shared passion for scientific
Related reading